| EN

Simcere Published its First Environmental, Social and Governance (ESG) Report

Release time:2021-05-26


On May 25, 2021, Simcere Pharmaceutical Group LTD. (2096.HK) released its first Environmental, Social and Governance (ESG) report. It mainly discloses the practice and achievements of the Group in product liability, environmental protection, social welfare and other aspects in 2020.

01:Patient Foremost, Quality Firsts



The Group always believes that quality management is essential to ensure product quality and maintain corporate reputation and success. Upholding the quality policy of “the Best Products, the Pursuit of Excellence”, we have comprehensively established a standardized quality management system, conduct quality control throughout the entire process of drug research and development, production and sales, and actively create a good quality management culture to provide comprehensive protection for the safety of patient medication.




02:Employee-Oriented, Care First

The Group strictly abides by the Labor Law of the People’s Republic of China and other relevant domestic and foreign laws and regulations, and industry regulations including GMP and GSP. It has prepared talent management systems, such as the Recruitment Management System, the Technical Post Management System and etc., to regulate employee management and protect employees’ rights and interests.


03:Safety and Environmental Protection, Responsibility First

The Group highly recognises the importance of work safety and green operation to the sustainable development. In 2020, Simcere Pharmaceutical, Hainan Simcere, Wuhu Simcere and Shandong Simcere, being subsidiaries of the Group, all passed the certification of ISO 14001 Environmental Management System.

04:Repaying the Society with Warmth

Committed to the corporate development, the Group also actively assumes and fulfills the corporate social responsibility, and makes important contributions to the battle against COVID-19, poverty alleviation through education, response to material natural disasters and crisis events and serious illness relief, repaying the society with warmth and playing a role as a corporate citizen.

  • In the period of fighting COVID-19, we donateed antiviral drugs and medical supplies with a market value of about RMB 4.9 million to designated hospitals and medical institutions of Wuhan City, Jiangsu Province and Nanjing City, and RMB 1 million to Wuhan City.

  • The Group produced three products available for fighting the virus and relieving symptoms relentlessly for 24 hours and delivered such products without any delay to hospitals in Wuhan City, and also sent them to more than 300 designated hospitals of 27 provinces and cities including Beijing, Shanghai, etc.


  • Early in 2020, at that critical time of epidemic containment, 140,000 masks were sourced and donated to the epidemic prevention frontline.

  • The Group has been supporting Simcere Hope Primary School in Lianshui County, Jiangsu Province and hope primary school in Lu’an City, Anhui Province since its establishment, and Yushu Bayi Orphan school since 2010.


Future Expectations

In 2020, we have actively explored for sustainable development practices, actively fulfilled our social responsibility and harmonized the corporate development with contributions to the environment and the society. 

Looking to 2021, we will work harder to achieve greater progress, pay close attention to the expectations of stakeholders, further improve the ESG management system, and incorporate the sustainable development concept into the corporate development more profoundly and organically.